RHHBY:OTCQX-Roche Holding Ltd ADR (Sponsored) (USD)

COMMON STOCK | Drug Manufacturers - General | OTCQX Marketplace

Last Closing

USD 34.93

Change

+0.27 (+0.78)%

Market Cap

USD 217.41B

Volume

0.20M

Analyst Target

USD 50.10
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Roche Holding AG is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-27 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZNCF AstraZeneca PLC

N/A

USD 244.48B
RHHVF Roche Holding AG Participation

N/A

USD 230.69B
RHHBF Roche Holding AG

N/A

USD 228.39B
NVSEF Novartis AG

N/A

USD 219.86B
SNYNF Sanofi

N/A

USD 116.35B
GLAXF GSK plc

N/A

USD 79.44B
DSKYF Daiichi Sankyo Company Limited

N/A

USD 67.69B
DSNKY Daiichi Sankyo Co Ltd ADR

N/A

USD 66.04B
CHGCY Chugai Pharmaceutical Co Ltd A..

N/A

USD 54.01B
CHGCF Chugai Pharmaceutical Co. Ltd

N/A

USD 50.41B

ETFs Containing RHHBY

SPWO S&P World ETF 1.53 % 0.00 %

N/A

USD 0.01B
PTIN Pacer Trendpilot Internat.. 0.00 % 0.00 %

N/A

USD 0.15B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (OTCQX Marketplace)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.59% 53% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.59% 49% F 46% F
Trailing 12 Months  
Capital Gain -8.34% 51% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.34% 47% F 49% F
Trailing 5 Years  
Capital Gain -0.48% 53% F 66% D+
Dividend Return 3.60% 31% F 13% F
Total Return 3.12% 56% F 63% D
Average Annual (5 Year Horizon)  
Capital Gain -2.15% 42% F 34% F
Dividend Return -1.48% 33% F 32% F
Total Return 0.67% 21% F 16% F
Risk Return Profile  
Volatility (Standard Deviation) 16.45% 83% B 90% A-
Risk Adjusted Return -8.97% 31% F 29% F
Market Capitalization 217.41B 95% A 100% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector